Osteoporosis International

, Volume 24, Issue 9, pp 2493–2498 | Cite as

Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study

  • S. R. Majumdar
  • S. N. Morin
  • L. M. Lix
  • W. D. Leslie
Original Article



Although systemic glucocorticoids are commonly used, it is difficult to obtain accurate exposure history. In 50,000 patients, we confirmed that glucocorticoids were associated with reductions in bone mineral density (BMD) and increases in fracture and documented that recent and prolonged durations of exposure were particularly associated with adverse events—dose information did not improve risk prediction.


Systemic glucocorticoid use, defined as ever having taken supra-physiologic doses for 90-days or more, is a risk factor for low BMD and fractures. This definition does not distinguish recent (vs remote) exposure.


Within a population-based clinical BMD registry in Manitoba, Canada, we identified all adults over age 40 years tested between 1998 and 2007 and then undertook a cohort study. We identified all oral glucocorticoid dispensations from 1995 to 2009 and stratified exposure by timing (“recent” if within 12 months vs “remote”) and duration (short [<90 days] vs prolonged [≥90 days]). Osteoporosis-related risk factors and treatments and major fractures were obtained using administrative health data.


A total of 12,818 of 52,070 (25 %) subjects had used glucocorticoids prior to BMD testing; the most common exposure was remote short (n = 6453) vs recent prolonged (n = 2896) vs recent short (n = 2644) vs remote prolonged (n = 825). Compared to 39,252 never-users, only recent prolonged glucocorticoid use was significantly associated with femoral neck T-score (ANCOVA-adjusted difference −0.13, 95 % CI −0.16 to −0.10, p < 0.001). There were 2,842 major (566 hip) fractures over median 5-year follow-up. Compared with never-users, only recent prolonged glucocorticoid use was significantly associated with BMD-independent increases in risk of incident major fracture (5.4 vs 7.7 %, adjusted HR 1.25, 95 % CI 1.07–1.45, p = 0.004) and hip fracture (1.1 vs 1.8 %, adjusted HR 1.61, 95 % CI 1.18–2.20, p = 0.003).


Recent and prolonged glucocorticoid use (but neither remote nor recent short courses) was independently associated with reduced BMD and increased risk of fractures. These findings should permit clinicians to identify a high-risk group of patients that might benefit from osteoporosis prevention.


BMD Fracture risk Glucocorticoids Osteoporosis Prediction Side effects 


  1. 1.
    Majumdar SR, Lix LM, Yogendran M, Morin SN, Metge CJ, Leslie WD (2012) Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998–2008). J Clin Endocrinol Metab 97:1236–1242PubMedCrossRefGoogle Scholar
  2. 2.
    Weinstein RS (2011) Glucocorticoid induced bone disease. N Engl J Med 365:62–70PubMedCrossRefGoogle Scholar
  3. 3.
    Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S et al (2012) A framework for the development of guidelines for the management of glucocorticoid induced osteoporosis. Osteoporos Int 23:2257–2276PubMedCrossRefGoogle Scholar
  4. 4.
    Van Staa TP, Luefkens HG, Cooper C (2002) The epidemiology of corticosteroid induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis JA, Johansson H, Oden A, Johnell O, de Laet C et al (2004) A meta-analysis of prior corticosteroid use fracture risk. J Bone Miner Res 19:893–899PubMedCrossRefGoogle Scholar
  6. 6.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative dose. Rheumatology 39:1383–1389PubMedCrossRefGoogle Scholar
  7. 7.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000PubMedCrossRefGoogle Scholar
  8. 8.
    De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRefGoogle Scholar
  9. 9.
    Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816PubMedCrossRefGoogle Scholar
  10. 10.
    Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its application to clinical practice. Bone 44:734–743PubMedCrossRefGoogle Scholar
  11. 11.
    Leslie WD, Lix LM, Tsang JF (2007) Single-site vs multi-site bone density measurement for fracture prediction. Arch Intern Med 167:1641–1647PubMedCrossRefGoogle Scholar
  12. 12.
    Leslie WD, Caetano PA, MacWilliam LR, Finlayson GS (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8:25–30PubMedCrossRefGoogle Scholar
  13. 13.
    Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterol 138:896–904CrossRefGoogle Scholar
  14. 14.
    Majumdar SR, Ezekowitz JA, Lix LM, Leslie WD (2012) Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. J Clin Endocrinol Metab 97:1179–1186PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2013

Authors and Affiliations

  • S. R. Majumdar
    • 1
    • 5
  • S. N. Morin
    • 2
  • L. M. Lix
    • 3
  • W. D. Leslie
    • 4
  1. 1.Department of MedicineUniversity of AlbertaEdmontonCanada
  2. 2.Department of MedicineMcGill UniversityMontrealCanada
  3. 3.Department of Community Health SciencesUniversity of ManitobaWinnipegCanada
  4. 4.Departments of Medicine and RadiologyUniversity of ManitobaWinnipegCanada
  5. 5.2 F1.24 Walter Mackenzie Health Sciences CentreUniversity of Alberta HospitalEdmontonCanada

Personalised recommendations